ANCA-associated vasculitis (AAV) patients undergoing dialysis for kidney failure have a lower risk of relapse, but a higher risk of infection and death, according to a review study. These findings help piece together evidence “to provide guidance for managing these patients and to guide future research opportunities,” researchers wrote.
News
People with relapsing ANCA-associated vasculitis (AAV) who achieved remission with rituximab and glucocorticoids have less than half the risk of experiencing a new relapse if they continue on rituximab treatment than if they start daily oral azathioprine. That’s according to the full results of the Phase 3…
ANCA-associated vasculitis (AAV) patients with proteinuria, elevated protein levels in their urine, after induction treatment are at a three times higher risk of kidney failure and/or death, according to a study based on data from five clinical trials. Data also linked persistent hematuria, or blood in the urine, after…
The European Alliance of Associations for Rheumatology (EULAR) has updated its recommendations on managing ANCA-associated vasculitis (AAV) based on new research and clinical data. Four overarching principles were introduced — the importance of patient-physician joint decisions, disease education, routine screening for treatment side effects and additional medical conditions,…
Nearly one-fifth of ANCA-associated vasculitis (AAV) patients in Japan have osteonecrosis of the femoral head (ONFH), a condition marked by the disruption of blood flow to the head of the femur, or thigh bone, a study showed. In most cases, the hip joints already collapsed or were at risk…
People with granulomatosis with polyangiitis (GPA) are more likely to develop an aneurysm — a bulge in a blood vessel wall that can burst or rupture — than those with other types of ANCA-associated vasculitis (AAV), according to a small study in France. Aneurysms mainly affected medium-sized vessels, especially…
Physicians in the U.S. are excited about the potential of Tavneos (avacopan), an approved treatment for people with ANCA-associated vasculitis (AAV), to reduce the use of corticosteroids, a type of steroid medication, in this patient population. That enthusiasm is due to the safety concerns associated with the long-term…
More than one-third of people with granulomatosis with polyangiitis (GPA), a type of ANCA-associated vasculitis, may experience eye symptoms, a study in Italy has found. In many cases, eye symptoms were present from the onset of disease, sometimes even preceding more specific symptoms affecting other body parts. “Patients should…
Many people with ANCA-associated vasculitis (AAV) have profound fatigue that’s severe enough to fulfill the diagnostic criteria for chronic fatigue syndrome, even when the disease isn’t active, a study shows. “We emphasize that physicians should be aware of this when assessing treatment and management strategies for improving quality…
Tavneos (avacopan) was generally safe and well tolerated in adults with severe ANCA-associated vasculitis treated under a global early access program (EAP) before the therapy’s approval, a study showed. EAPs make investigational therapies available outside clinical trials to people with serious or life-threatening conditions who have few or no…
Recent Posts
- New analysis identifies phase-specific relapse risks in AAV treatment
- Sharing with others about vasculitis can strengthen connections
- New nanoparticle approach targets kidney damage in vasculitis
- Study points to 2 biomarkers for AAV disease activity, relapse
- Monitoring our kidney health is crucial with ANCA vasculitis